This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Sangamo Nerve Regrowth Drug Fails Key Test

Updated with stock price.

RICHMOND, Calif. ( TheStreet) -- Sangamo Biosciences' (SGMO) experimental drug SB-509 failed to restore the health and function of damaged leg nerves in patients with severe diabetic neuropathy, according to results from a mid-stage study released Monday.

Due to the negative results from the study, Sangamo said it will halt further clinical development of SB-509 and focus instead on other pipeline drugs, including a gene therapy for HIV.

Shares of Sangamo were down $1.59, or 36%, to $2.76 in Monday pre-market trading. The stock closed Friday at $4.35.

The failure of SB-509 is a setback for Sangamo and its so-called "zinc finger" drug technology, which the company has been developing for years on its own. SB-509 is a protein -- or "zinc finger" -- custom engineered to turn on (or restore activity) in the gene for vascular endothelial growth factor. The so-called VEGF-A protein is responsible for nerve and blood vessel growth.

In the phase IIb study, SB-509 treatment failed to demonstrate statistically significant improvements from baseline compared with placebo at 180 days in two key measures of nerve regeneration and function -- sural nerve conduction velocity (sNCV) or neuropathy impairment score in the lower limb (NIS-LL). The study enrolled 150 patients with severe diabetic neuropathy.

A high level of blood sugar that damages blood vessels feeding nerves is the root cause of diabetic neuropathy. Eventually, the damaged nerves lose function and even die, leading to tingling, numbness and pain. The only drugs approved for diabetic neuropathy today are painkillers and anti-depressants like Pfizer's (PFE) Lyrica or Eli Lilly's (LLY) Cymbalta, none of which address the root problem of nerve damage or offer a way to reverse it.

Previous studies showed Sangamo's SB-509 improved nerve fiber density and nerve fiber health, but these biologic measurements did not translate into significant or meaningful improvements in the "real world" clinical symptoms of diabetic neuropathy, particularly in patients with mild to moderate forms of the disease.

Sangamo hoped to show more robust results in this current trial by restricting enrollment to patients with more severe nerve damage from diabetic neuropathy.

Last month, Sangamo released results from a early-stage study of a gene therapy for HIV.

--Written by Adam Feuerstein in Boston.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,279.74 +13.75 0.08%
S&P 500 2,010.40 -0.96 -0.05%
NASDAQ 4,579.7890 -13.6380 -0.30%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs